Abstract:Abstract Background Our previous study explored Amphotericin B (AMB) plus 5-flucytosine (5-FC) combined with fluconazole (FLU) therapy in the induction period, which seemed to be better than the previous AMB + 5-FC antifungal therapy in non-HIV and non-transplant-associated CM. However, based on our clinical finding, the outcomes of some CM patients who received AMB plus 5-FC combined with FLU antifungal therapy were still poor. Therefore, we need to explore new antifungal methods in non-HIV and non-transplant-associated CM during the induction period. Methods Clinical data from 148 patients admitted to the Third Affiliated Hospital of Sun Yat Sen University from January 2011 to December 2020 were collected. These patients were stratified based on antifungal treatment methods in the induction period (group I with AMB + 5-FC + VOR, group II with AMB + 5-FC + FLU, group III with AMB + 5-FC). Results The first hospitalization time of Group I (median: 25 days, IQR: 20–34.5) was significantly shorter than that of Group II (median: 43 days, IQR: 29–62) (p < 0.001) and Group III (median: 50.5 days, IQR: 43–77.5) (p < 0.001). After 2 weeks of follow-up, Group I (26/49) had more patients reaching CSF clearance (p = 0.004) than Group II (18/71) and Group III (7/28). In multivariable analysis, Group II (OR: 3.35, 95%CI 1.43–7.82, p = 0.005) and Group III (OR: 3.8, 95%CI 1.23–11.81, p = 0.021) were associated with higher risk about CSF clearance failure at 2 weeks follow-up than Group I. After 10 weeks of follow-up, the incidence of hypokalemia in Group I was significantly lower than that in Group II (p = 0.003) and Group III (p = 0.004), and the incidence of gastrointestinal discomfort in Group I was significantly lower than that in Group II (p = 0.004). Conclusion AMB plus 5-FC combined with VOR may rapidly improve clinical manifestation, decrease CSF OP and clear the cryptococci in CSF during the early phase, substantially shorten the hospitalization time, and reduce the incidences of hypokalemia and gastrointestinal discomfort.

[Pharmacokinetics of Amphotericin B in the Cerebrospinal Fluid During Continuous Intrathecal Administration for Treatment of Cryptococcal Neoformans Meningitis].

Short-Course Rather Than Low-Dose Amphotericin B May Exert Potential Influence on Mortality in Cryptococcal Meningitis Patients Treated with Amphotericin B Plus Flucytosine Alone or in Combination with Fluconazole

Concentrations of amphotericin B in body fluid from patients with AIDS-associated cryptococcal meningitis

The Role of an Ommaya Reservoir in the Management of Children with Cryptococcal Meningitis

RP-HPLC Determination of Amphotericin B in Cerebrospinal Fluid of Patients with Cryptococcal Meningitis

[Clinical Study of Amphotericin B in the Treatment of Invasive Fungal Infection in 111 Hematological Disorder Patients with Neutrocytopenia].

Observation on the treatment efficacy of Cryptococcal neoformans meningitis

Treatment of cryptococcal meningitis with low-dose amphotericin B and flucytosine.

Efficacy of Intravenous Amphotericin B-polybutylcyanoacrylate Nanoparticles Against Cryptococcal Meningitis in Mice

In Vitro and in Vivo Evidence for Amphotericin B As a P-glycoprotein Substrate on the Blood-Brain Barrier.

Amphotericin B Plus Fluorocytosine Combined with Voriconazole for the Treatment of Non-Hiv and Non-Transplant-associated Cryptococcal Meningitis: a Retrospective Study

Early Experiences with Intrathecal Administration of Amphotericin B Liposomal Formulation at a Neurosurgical Center

Triple therapy versus amphotericin B plus flucytosine for the treatment of non-HIV- and non-transplant-associated cryptococcal meningitis: retrospective cohort study.

Clinical analysis of cryptococcal meningitis:21 cases

[Evaluation of Low-Dose Amphotericin B and Flucytosine in the Treatment of Cryptococcal Meningitis].

Clinical analysis of 14 cases of cryptococcus neoformans meningitis

UV–Vis spectrophotometry for rapid and specific quantification of amphotericin B: analytical method validation for ex vivo and in vivo studies in the development of nanoemulsion-incorporated thermosensitive gel

Preparation of amphotericin B-polybutylcyanoacrylate-loaded nanoparticles and its distribution in mice

A sensitive HPLC method for determination of amphotericin B and itraconazole in cerebrospinal fluid and its application to patients with cryptococcal meningitis

Noncovalent Complexation of Amphotericin B with Poly(β-Amino Ester) Derivates for Treatment of C. Neoformans Infection

The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis.